These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28837921)

  • 1. Discovery of BAZ2A bromodomain ligands.
    Spiliotopoulos D; Wamhoff EC; Lolli G; Rademacher C; Caflisch A
    Eur J Med Chem; 2017 Oct; 139():564-572. PubMed ID: 28837921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Analysis of Small-Molecule Binding to the BAZ2A and BAZ2B Bromodomains.
    Dalle Vedove A; Spiliotopoulos D; D'Agostino VG; Marchand JR; Unzue A; Nevado C; Lolli G; Caflisch A
    ChemMedChem; 2018 Jul; 13(14):1479-1487. PubMed ID: 29770599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing.
    Dalle Vedove A; Cazzanelli G; Batiste L; Marchand JR; Spiliotopoulos D; Corsi J; D'Agostino VG; Caflisch A; Lolli G
    ACS Med Chem Lett; 2022 Sep; 13(9):1434-1443. PubMed ID: 36105334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a BAZ2A Bromodomain Hit Compound by Fragment Joining.
    Dalle Vedove A; Cazzanelli G; Corsi J; Sedykh M; D'Agostino VG; Caflisch A; Lolli G
    ACS Bio Med Chem Au; 2021 Dec; 1(1):5-10. PubMed ID: 36147311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
    Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Throughput Fragment Docking into the BAZ2B Bromodomain: Efficient in Silico Screening for X-Ray Crystallography.
    Lolli G; Caflisch A
    ACS Chem Biol; 2016 Mar; 11(3):800-7. PubMed ID: 26942307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluation of bromodomain ligands targeting BAZ2A.
    Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
    Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
    Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
    J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derivatives of 3-Amino-2-methylpyridine as BAZ2B Bromodomain Ligands: In Silico Discovery and in Crystallo Validation.
    Marchand JR; Lolli G; Caflisch A
    J Med Chem; 2016 Nov; 59(21):9919-9927. PubMed ID: 27731638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
    Chen P; Chaikuad A; Bamborough P; Bantscheff M; Bountra C; Chung CW; Fedorov O; Grandi P; Jung D; Lesniak R; Lindon M; Müller S; Philpott M; Prinjha R; Rogers C; Selenski C; Tallant C; Werner T; Willson TM; Knapp S; Drewry DH
    J Med Chem; 2016 Feb; 59(4):1410-24. PubMed ID: 25799074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
    Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based in silico screening of bromodomain ligands.
    Spiliotopoulos D; Caflisch A
    Drug Discov Today Technol; 2016 Mar; 19():81-90. PubMed ID: 27769362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
    Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
    J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Inhibitors of Four Bromodomains by Fragment-Anchored Ligand Docking.
    Marchand JR; Dalle Vedove A; Lolli G; Caflisch A
    J Chem Inf Model; 2017 Oct; 57(10):2584-2597. PubMed ID: 28862840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B.
    Drouin L; McGrath S; Vidler LR; Chaikuad A; Monteiro O; Tallant C; Philpott M; Rogers C; Fedorov O; Liu M; Akhtar W; Hayes A; Raynaud F; Müller S; Knapp S; Hoelder S
    J Med Chem; 2015 Mar; 58(5):2553-9. PubMed ID: 25719566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based discovery of selective BRPF1 bromodomain inhibitors.
    Zhu J; Zhou C; Caflisch A
    Eur J Med Chem; 2018 Jul; 155():337-352. PubMed ID: 29902720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty Crystal Structures of Bromodomain and PHD Finger Containing Protein 1 (BRPF1)/Ligand Complexes Reveal Conserved Binding Motifs and Rare Interactions.
    Zhu J; Caflisch A
    J Med Chem; 2016 Jun; 59(11):5555-61. PubMed ID: 27167503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of the TAM domain of BAZ2A in binding to DNA or RNA independent of methylation status.
    Chen S; Zhou M; Dong A; Loppnau P; Wang M; Min J; Liu K
    J Biol Chem; 2021 Dec; 297(6):101351. PubMed ID: 34715126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation.
    Yang Z; Zhou Y; Zhong L
    Bioorg Med Chem Lett; 2021 Feb; 33():127745. PubMed ID: 33333161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.